Hvivo
HVO · AIM · Health Care · mcap £41m · 6.0p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 22 Sep 26 | Board change | Directorate Change
Caroline Shaw appointed as Independent Non-Executive Director; Elaine Sullivan steps down. |
−0.8% |
| 15 Sep 26 | Results | Half-year Results
H1 2026 revenue £16.3m; contracted orderbook doubled to £65m; CRS Berlin acquisition completed; H2 expected to nearly double H1 revenue. |
−4.7% |
| 15 Sep 26 | Board change | Chief Financial Officer Succession
CFO Stephen Pinkerton retiring after 10 years; Richard Cotton appointed Interim CFO pending permanent successor. |
−4.7% |
| 08 Sep 26 | Holding | Holding(s) in Company | |
| 04 Sep 26 | Routine | Notice of Results | |
| 27 Aug 26 | HVIVO acquires CRS Berlin
hVIVO acquires CRS Berlin, a German Phase I/II clinical research unit, expanding into dermatology and women's health. |
+1.6% | |
| 27 Aug 26 | HVIVO acquires CRS Berlin, expanding expertise into dermatology and women's health markets
hVIVO acquires CRS Berlin, a Phase I/II clinical research unit, for nominal upfront plus revenue-based earnouts. |
+1.6% | |
| 23 Jul 26 | Trading update | H1 2026 Trading Update
H1 revenue £16.3m, orderbook more than doubled to £65m with strong commercial momentum. |
−0.7% |
| 13 Jul 26 | Change of Auditor
London, UK - 13 July 2026, the board of hVIVO plc (AIM: HVO), a purpose built, full-service international clinical development partner and the world leader in human challenge trials, has agreed to appoint Grant Thornton |
+0.0% | |
| 09 Jun 26 | Holding | Holding(s) in Company | |
| 01 Jun 26 | Consultancy contract with Decoy Therapeutics
hVIVO signs consultancy contract with Decoy Therapeutics to support respiratory antiviral clinical development. |
−0.6% | |
| 29 May 26 | Routine | Grant of awards under Long Term Incentive Plan | |
| 20 May 26 | Capital Markets Day
hVIVO to showcase integrated, full service early clinical development platform at Capital Markets Day |
+0.6% | |
| 13 May 26 | Routine | Result of AGM | |
| 12 May 26 | Holding | Holding(s) in Company | |
| 07 May 26 | £6m Influenza HCT contract signed
hVIVO signs £6m influenza human challenge trial contract with clinical-stage biopharmaceutical company. |
+8.0% | |
| 24 Apr 26 | Director dealing | Director/PDMR Shareholding | |
| 22 Apr 26 | HCT contract signed with ILiAD Biotechnologies
hVIVO signed contract to conduct pivotal Phase III human challenge trial for ILiAD's whooping cough vaccine BPZE1. |
−0.5% | |
| 17 Apr 26 | Results | Annual Report & Notice of AGM
London, UK - 17 April 2026, hVIVO plc (AIM: HVO), a purpose-built, full-service international clinical development partner and the world leader in human challenge trials, confirms that the Company's Annual Report and Acc |
+4.7% |
| 15 Apr 26 | Results | Final Results
Revenue fell to £46.8m from £62.7m due to HCT cancellations; adjusted EBITDA £1.4m; acquisitions completed to diversify service offerings. |
−2.9% |
| 14 Apr 26 | HVIVO launches unified brand identity
hVIVO launches unified brand identity following integration of acquired businesses into single platform. |
+17.6% | |
| 14 Apr 26 | Influenza HCT contract signed with Traws Pharma
hVIVO signs clinical trial agreement with Traws Pharma to conduct Phase 2a influenza human challenge trial. |
+17.6% | |
| 07 Apr 26 | Routine | Notice of Results | |
| 26 Mar 26 | Holding | Holding(s) in Company | |
| 27 Feb 26 | Holding | Holding(s) in Company | |
| 23 Feb 26 | Routine | Issue of Equity and Total Voting Rights | |
| 16 Feb 26 | Holding | Holding(s) in Company | |
| 11 Feb 26 | Holding | Holding(s) in Company | |
| 29 Jan 26 | Trading update | Trading Update
FY25 revenue £46.7m in line, positive adjusted EBITDA ahead of expectations, guidance maintained for 2026. |
+3.3% |
| 27 Jan 26 | Notice of Trading Update
hVIVO to issue trading update for year ended 31 December 2025 on 29 January 2026. |
+1.7% | |
| 18 Dec 25 | Board change | Appointment of Non-Executive Director
Richard Cotton appointed as Independent Non-Executive Director and Audit Committee Chair. |
+6.9% |
| 15 Dec 25 | Board change | CEO & CFO Share Purchase
CEO and CFO purchased shares in the company on the open market. |
+25.5% |
| 27 Nov 25 | MSD to acquire Cidara
Client Cidara acquired by MSD for $9.2bn following positive Phase IIb trial results supported by hVIVO. |
−1.7% | |
| 20 Nov 25 | >£5 million CRS contracts signed
hVIVO's German subsidiary CRS signs contracts worth over £5 million with five early-phase clinical trial clients. |
+0.8% | |
| 11 Nov 25 | Positive data from novel human challenge models
hVIVO presented positive data from three newly developed human challenge models at major scientific conferences. |
+2.4% | |
| 06 Nov 25 | Holding | Holding(s) in Company | |
| 03 Nov 25 | Presentation at Jefferies Healthcare Conference
hVIVO to present at Jefferies Global Healthcare Conference |
−0.5% | |
| 27 Oct 25 | Holding | Holding(s) in Company |
Company filings. Not investment advice.